Kadcyla 160mg (Trastuzumab emtansine Vials) 160mg

Kadcyla 160mg (trastuzumab emtansine) is a targeted therapy used in oncology. This 160mg vial formulation is designed for intravenous administration under medical supervision. Store between 2-8°C to maintain potency. Always handle with care per healthcare provider instructions.

Strength

160mg

Pack Size

Storage

2-8°

Manufacturer / TM Owner

F.Hoffman La Roche Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Trastuzumab emtansine is used to treat certain types of HER2-positive breast cancer. It combines trastuzumab with a chemotherapy agent to target cancer cells specifically. Patients often ask what trastuzumab emtansine is used for in metastatic or early-stage treatment settings. This medication is typically prescribed after prior HER2-targeted therapies.

Side Effects

As a targeted therapy, trastuzumab emtansine works by binding to HER2 receptors on cancer cells and delivering chemotherapy directly to them. This approach aims to reduce damage to healthy cells compared to traditional chemotherapy. Common effects may include fatigue, nausea, or changes in blood cell counts during treatment.

Precautions & Warnings

Kadcyla 160mg requires careful handling and storage between 2-8°C. Always follow healthcare provider instructions for preparation and administration. Patients should report any signs of infection, bleeding, or unusual symptoms immediately. Avoid exposure to extreme temperatures or direct sunlight during transport.

Avoid Interactions

Trastuzumab emtansine may interact with other medications that affect liver enzymes, such as certain CYP inhibitors or inducers. Patients should inform their healthcare provider about all prescription, over-the-counter, and herbal products they are using. Live vaccines should be avoided during treatment. Alcohol consumption may exacerbate certain side effects.

References

Frequently Asked Questions

Trastuzumab emtansine is used to treat HER2-positive breast cancer in specific patient populations.

Kadcyla 160mg is administered intravenously by healthcare professionals in a clinical setting.

Common effects may include fatigue, nausea, or changes in blood cell counts during treatment.

No, Kadcyla 160mg must be stored between 2-8°C to maintain its potency.

Yes, it may interact with medications that affect liver enzymes or live vaccines.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.